Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Recruiting 44Not yet recruiting 20Active not recruiting 17Completed 7Withdrawn 5Unknown 1Terminated 1Suspended 1

Sponsor Class

OTHER 5INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Head & Neck 2Thoracic 1Lymphoid 1Genitourinary 1CNS 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Oropharyngeal Neoplasms 1Mycosis Fungoides 1Lung Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Radiotherapy 91pembrolizumab 88Cyclophosphamide 84Gemcitabine 70Cisplatin 70Magnetic Resonance Spectroscopy 65Carboplatin 60Radiosurgery 55Paclitaxel 55Nivolumab 48Dexamethasone 45Bevacizumab 42Biopsy 41Fluorouracil 39durvalumab 37Surveys and Questionnaires 36Docetaxel 36fludarabine 35Doxorubicin 35Radiation 33Oxaliplatin 33Capecitabine 33Rituximab 32fludarabine phosphate 31Leucovorin 31Cytarabine 30Melphalan 29Etoposide 28Pemetrexed 27Irinotecan 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Withdrawn × OTHER × cemiplimab × Clear all
NCT05538988 2025-06-27

BIOSELECT

AHS Cancer Control Alberta

Phase 1/2 Withdrawn
Lymphoid

Mycosis Fungoides

NCT05840770 2025-05-26

Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer

City of Hope Medical Center

Phase 2 Withdrawn
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03477864 2025-04-29

Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer

Thomas Jefferson University

Phase 1 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT05535023 2023-09-13

Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms

NCT04831450 2022-08-04

Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)

University of Miami

Phase 2 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡